Posted by Michael Wonder on 22 Aug 2024
Clarity receives FDA fast track designation for 64Cu-SAR-bisPSMA
22 August 2024 - Clarity Pharmaceuticals is pleased to announce that the US FDA has granted fast track designation for 64Cu-SAR-bisPSMA for positron emission tomography imaging of prostate-specific membrane antigen positive prostate cancer lesions with suspected metastasis who are candidates for initial definitive therapy.
Clarity's on-going clinical program with 64Cu-SAR-bisPSMA includes trials in two indications: prostate cancer patients prior to undergoing radical prostatectomy, and with biochemical recurrence of their disease.
